China Isotope & Radiation (HKSE:01763) ROCE % : 14.22% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Isotope & Radiation's annualized ROCE % for the quarter that ended in Dec. 2023 was 14.22%.

China Isotope & Radiation ROCE % Historical Data

The historical data trend for China Isotope & Radiation's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation ROCE % Chart

China Isotope & Radiation Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

14.04

10.55

13.18

12.84

11.37

China Isotope & Radiation Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial											16.68	9.80	17.02	9.35	14.22

China Isotope & Radiation ROCE % Calculation

China Isotope & Radiation's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1048.473	/	( ( (13165.757 - 4501.938)	+	(14428.814 - 4652.849) )	/ 2 )
	=	1048.473	/	( (8663.819	+	9775.965)	/ 2 )
	=	1048.473	/	9219.892
	=	11.37 %

China Isotope & Radiation's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	1296.556	/	( ( (12903.126 - 4440.945)	+	(14428.814 - 4652.849) )	/ 2 )
	=	1296.556	/	( ( 8462.181	+	9775.965 )	/ 2 )
	=	1296.556	/	9119.073
	=	14.22 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

China Isotope & Radiation (HKSE:01763) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Isotope & Radiation ROCE % Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Isotope & Radiation (HKSE:01763) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089

Website

https://www.china-isotope.com

China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines